Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis

Clinical Cancer Research

Volumn 16, Issue 7, 2010, Pages 1988-1996

  Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; INCB 018424; LESTAURTINIB; TG 101348; UNCLASSIFIED DRUG; XL 019;

ANEMIA; CANCER CENTER; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME REGULATION; EXERCISE; FATIGUE; FOLLOW UP; HEMATOPOIETIC STEM CELL; HUMAN; HYPERLIPASEMIA; HYPERTRANSAMINASEMIA; INFECTION; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MYELOFIBROSIS; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NIGHT SWEAT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTOPENIA;

ANIMALS; CYTOSTATIC AGENTS; HUMANS; JANUS KINASE 2; MODELS, BIOLOGICAL; MUTANT PROTEINS; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS;

EID: 77950647838     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2836     Document Type: Review

References (68)

1. Mesa RA. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Hematol Am Soc Hematol Educ Program 2007;2007:355-362
2. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452-2466
3. Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematol Am Soc Hematol Educ Program 2003:200-224
4. Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007;109: 2083-2088
5. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006;81:159-166
6. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761
7. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-2901
8. Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006;32: 174-207.
9. Pearson TC, Messinezy M, Westwood N, et al. A polycythemia vera updated: diagnosis, pathobiology, and treatment. Hematol Am Soc Hematol Educ Program 2000:51-68.
10. Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107:4214-4222
11. Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 2008;87:1-10.
12. Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 2006; 106:1985-1989
13. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110:1092-1097
14. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007;109: 68-76.
15. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996;88:1013-1018
16. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998;102: 684-690
17. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000;95:2226-2233
18. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342:1255-1265
19. Panteli KE, Hatzimichael EC, Bouranta PK, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005;130: 709-715
20. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006;107:361-370
21. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematol Am Soc Hematol Educ Program 2006:240-245
22. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061
23. James C. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases? Hematol Am Soc Hematol Educ Program 2008;2008:69-75.
24. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352: 1779-1790
25. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-397
26. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-22792
27. Shide K, Shimoda HK, Kumano T, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008;22:87-95.
28. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008;111:3931-3940
29. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008;111:5109-5117
30. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007;110:840-846
31. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
32. Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol 2007;35:1641-1646
33. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-468
34. Yamaoka K, Saharinen P, Pesu M, Holt VE III, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol 2004;5:253-256
35. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007;178:2623-2629
36. Smithgall TE, Briggs SD, Schreiner S, Lerner EC, Cheng H, Wilson MB. Control of myeloid differentiation and survival by Stats. Oncogene 2000;19:2612-2618
37. Kota J, Caceres N, Constantinescu SN. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia 2008;22:1828-1840
38. Levine RL, Wernig G. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematol Am Soc Hematol Educ Program 2006;510:233-239
39. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110:4030-4036
40. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009;114:1477-1483
41. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008;22:756-761
42. Camoratto AM, Jani JP, Angeles TS, et al. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity. Int J Cancer 1997;72:673-679
43. Levis M, Stine A, Pham R, et al. Pharmacokinetic and pharmacodynamic studies of lestaurtinib (CEP-701) and PKC-412: cytotoxicity is often dependent on non-FLT30-mediated effects [abstract]. Blood 2005:2463.
44. George DJ, Dionne CA, Jani J, et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 1999;59:2395-2401
45. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010 Feb 3 (Epub ahead of print).
46. Fridman J, Nussenzveig R, Liu P, et al. Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders [abstract]. Blood 2007; 110:3538.
47. Verstovsek S, Kantarjian H, Mesa RA, et al. Long-term follow up and optimized dosing regimen of INCB018424 in patients with myelofibrosis: durable clinical, functional and symptomatic responses with improved hematological safety [abstract]. Blood 2009;114:315.
48. Tefferi A, Kantarjian H, Pardanani A, et al. The clinical phenotype of myelofibrosis encompasses a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1/2 [Abstract]. Blood 2008;112:2804.
49. Verstovsek S, Kantarjian H, Pardanani A, et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (Post PV/ETVF) [Abstract]. Blood 2008;112:1762.
50. Verstovsek S, Kantarjian H, Pardanani A, et al. Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: no change in V617F:wt JAK2 ratio in patients with high allele burdens despite profound clinical improvement following treatment with the JAK inhibitor, INCB018424 [abstract]. Blood 2008;112:2802.
51. Dobrzanski P, Hexner E, Serdikoff C, et al. CEP-701 is a JAK2 inhibitor which attenuates JAK2/STAT5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders [abstract]. Blood 2006;108:3594.
52. Weisel K, Yildirim S, Xue X, Kanz L, Mohle R. Selective FLT3 inhibition uncovers the role of FL and FLT3 in normal CD34+ hematopoietic stem cells [abstract]. Blood 2006:108.
53. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99:3885-3891
54. Strock CJ, Park JI, Rosen M, et al. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 2003;63: 5559-5563
55. Levis M, Smith BD, Beran M, et al. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition [abstract]. Blood 2005;106:403.
56. Santos FP, Kantarjian HM, Jain N, et al. Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115:1131-1136
57. Moliterno A, Roboz G, Carroll M, Luger S, Hexner E, Bensen-Kennedy D. An open-label study of CEP-701 in patients with JAK2 V617F-positive polycythemia vera and essential thrombocythemia [abstract]. Blood 2008;112:99.
58. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-1503
59. Hexner E, Goldberg J, Prchal J, et al. A multicenter, open label phase I/II study of CEP701 (Lestaurtinib) in adults with myelofibrosis; report on phase I: a study of the Myeloproliferative Disorders Research Consortium (MPD-RC) [abstract]. Blood 2009;114:314.
60. Paquette R, Sokol L, Shah N, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Blood 2008;112:2810.
61. Shah N, Olszynski P, Sokol L, Verstovsek S. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera or post-essential thrombocythemia myelofibrosis [Abstract]. Blood 2008;112:98.
62. Hood J, Cao J, Chow C, et al. Development of TG101348 for the treatment of JAK2-driven malignancies [abstract]. J Clin Oncol 2008;26:7083.
63. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-320
64. Ferrajoli A, Faderl S, Van Q, et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 2007;67:11291-11299
65. Pardanani A, Gotlib J, Jamieson C, et al. A phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden [abstract]. Blood 2009;114:314.
66. Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology 2009:636-642
67. Pardanani A, Gotlib J, Jamieson C, et al. TG101348, a JAK2-selective inhibitor, is well tolerated in patients with myelofibrosis and shows substantial therpeutic activity accompanied by a reduction in JAK2V617F allele burden [abstract]. 14th Congress of the European Hematology Association, Berlin (Germany). 2009 June 4-9.
68. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-683